{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:40:04Z","timestamp":1793367604512,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.suronc.2018.07.002","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T13:13:50Z","timestamp":1530623630000},"page":"544-550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Severity classification of Tenosynovial Giant Cell Tumours on MR imaging"],"prefix":"10.1016","volume":"27","author":[{"given":"M.J.L.","family":"Mastboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.G.M.","family":"Verspoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.F.","family":"Hanff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.J.","family":"Gademan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.D.S.","family":"Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.W.B.","family":"Schreuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.P.","family":"van der Wal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-7656","authenticated-orcid":false,"given":"M.A.J.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.suronc.2018.07.002_bib1","first-page":"356","article-title":"Pigmented villonodular synovitis (PVNS) of the knee joint: magnetic resonance imaging (MRI) using standard and dynamic paramagnetic contrast media. Report of 52 cases surgically and histologically controlled","volume":"107","author":"Barile","year":"2004","journal-title":"La Radiologia Medica."},{"key":"10.1016\/j.suronc.2018.07.002_bib2","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/cncr.26409","article-title":"Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis","volume":"118","author":"Cassier","year":"2012","journal-title":"Cancer."},{"key":"10.1016\/j.suronc.2018.07.002_bib3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","article-title":"CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study","volume":"16","author":"Cassier","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.suronc.2018.07.002_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/01.blo.0000224051.01873.fb","article-title":"What affects the recurrence and clinical outcome of pigmented villonodular synovitis?","volume":"450","author":"Chiari","year":"2006","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.suronc.2018.07.002_bib5","series-title":"Practical Statistics for Medical Research","author":"Altman","year":"1990"},{"key":"10.1016\/j.suronc.2018.07.002_bib6","series-title":"WHO Classification of Tumours of Soft Tissue and Bone","first-page":"102","article-title":"Tenosynovial giant cell tumour, diffuse type","author":"de St Aubain","year":"2013"},{"key":"10.1016\/j.suronc.2018.07.002_bib7","series-title":"WHO Classification of Tumours of Soft Tissue and Bone","first-page":"100","article-title":"Tenosynovial giant cell tumour, localized type","author":"de St Aubain","year":"2013"},{"key":"10.1016\/j.suronc.2018.07.002_bib8","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S1064-9689(21)00650-4","article-title":"The role of MR imaging in soft tissue tumor evaluation: perspective of the orthopedic oncologist and musculoskeletal pathologist","volume":"8","author":"Frassica","year":"2000","journal-title":"Magn. Reson. Imag. Clin. N. Am."},{"issue":"5","key":"10.1016\/j.suronc.2018.07.002_bib9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","article-title":"Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial","volume":"19","author":"Gelderblom","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.suronc.2018.07.002_bib10","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.otsr.2016.11.002","article-title":"Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)","volume":"103","author":"Gouin","year":"2017","journal-title":"Orthop Traumatol Surg Res."},{"key":"10.1016\/j.suronc.2018.07.002_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2017.75.8482","article-title":"Locally aggressive connective tissue tumors","volume":"36","author":"Gounder","year":"2018","journal-title":"J. Clin. Oncol. : Off. J. Am. Soc. Clinic. Oncol."},{"key":"10.1016\/j.suronc.2018.07.002_bib12","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1002\/cncr.26529","article-title":"Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor\/pigmented villonodular synovitis with radiotherapy and surgery","volume":"118","author":"Griffin","year":"2012","journal-title":"Cancer."},{"key":"10.1016\/j.suronc.2018.07.002_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF02425937","article-title":"Pigmented villonodular synovitis: MRI characteristics","volume":"24","author":"Hughes","year":"1995","journal-title":"Skeletal Radiol."},{"key":"10.1016\/j.suronc.2018.07.002_bib14","first-page":"7402570","article-title":"Limb amputation after multiple treatments of tenosynovial giant cell tumour: series of 4 Dutch cases","volume":"2017","author":"Mastboom","year":"2017","journal-title":"Case Rep. Orthopedics."},{"key":"10.1016\/j.suronc.2018.07.002_bib15","first-page":"1","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumors","author":"Mastboom","year":"2017","journal-title":"Acta Orthop."},{"key":"10.1016\/j.suronc.2018.07.002_bib16","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1148\/rg.285085134","article-title":"Pigmented villonodular synovitis: radiologic-pathologic correlation","volume":"28","author":"Murphey","year":"2008","journal-title":"Radiographics"},{"key":"10.1016\/j.suronc.2018.07.002_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/903873","article-title":"Intra-articular synovial sarcomas: incidence and differentiating features from localized pigmented villonodular synovitis","volume":"2015","author":"Nordemar","year":"2015","journal-title":"Sarcoma"},{"key":"10.1016\/j.suronc.2018.07.002_bib18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","article-title":"Tenosynovial giant cell tumour\/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors","volume":"51","author":"Palmerini","year":"2015","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.suronc.2018.07.002_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3928\/0147-7447-19900201-08","article-title":"The use of magnetic resonance imaging in the diagnosis of pigmented villonodular synovitis","volume":"13","author":"Poletti","year":"1990","journal-title":"Orthopedics"},{"key":"10.1016\/j.suronc.2018.07.002_bib20","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Canc. Cell"},{"key":"10.1016\/j.suronc.2018.07.002_bib21","series-title":"A Phase I\/II Dose Escalation and Expansion Study of Cabiralizumab (Cabira; FPA-008), an Anti-CSF1R Antibody, in Tenosynovial Giant Cell Tumor (TGCT, Diffuse Pigmented Villonodular Synovitis D-pvns). American Society of Clinical Oncology","author":"Sankhala","year":"2017"},{"key":"10.1016\/j.suronc.2018.07.002_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2016.04.022","article-title":"Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future perspectives","volume":"63","author":"Staals","year":"2016","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.suronc.2018.07.002_bib23","series-title":"ASCO Conference","article-title":"Final results of ENLIVEN: a global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT)","author":"Tap","year":"2018"},{"key":"10.1016\/j.suronc.2018.07.002_bib24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.suronc.2018.07.002_bib25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5435\/00124635-200606000-00007","article-title":"Pigmented villonodular synovitis","volume":"14","author":"Tyler","year":"2006","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"10.1016\/j.suronc.2018.07.002_bib26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jso.23220","article-title":"A multidisciplinary approach to giant cell tumors of tendon sheath and synovium\u2013a critical appraisal of literature and treatment proposal","volume":"107","author":"van der Heijden","year":"2013","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.suronc.2018.07.002_bib27","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1302\/0301-620X.96B8.33608","article-title":"Functional outcome and quality of life after the surgical treatment for diffuse-type giant-cell tumour around the knee: a retrospective analysis of 30 patients","volume":"96-B","author":"van der Heijden","year":"2014","journal-title":"Bone Joint Lett. J."},{"key":"10.1016\/j.suronc.2018.07.002_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/17453674.2016.1205168","article-title":"Arthroplasty for tenosynovial giant cell tumors","volume":"87","author":"Verspoor","year":"2016","journal-title":"Acta Orthop."},{"key":"10.1016\/j.suronc.2018.07.002_bib29","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/rheumatology\/keu230","article-title":"Long-term follow-up results of primary and recurrent pigmented villonodular synovitis","volume":"53","author":"Verspoor","year":"2014","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.suronc.2018.07.002_bib30","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.3892\/ol.2017.6011","article-title":"Giant cell tumor of the tendon sheath: magnetic resonance imaging findings in 38 patients","volume":"13","author":"Wang","year":"2017","journal-title":"Oncology Lett.."}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740418301506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740418301506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T22:29:03Z","timestamp":1661552943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740418301506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0960740418301506"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2018.07.002","relation":{},"ISSN":["0960-7404"],"issn-type":[{"value":"0960-7404","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severity classification of Tenosynovial Giant Cell Tumours on MR imaging","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2018.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}